The genes linked to human disease number in the thousands — but in all but a few hundred cases, researchers don’t understand the structure or activity of the proteins these genes encode, and therefore don’t have the data they need for traditional drug design. Atomwise uses convolutional neural networks, similar to those used in speech recognition or computer vision, to screen billions of synthesizable small molecules for those that might interact with target proteins, even without full structure data.
News & Insights
Powering a Comprehensive Response to the COVID-19 Crisis Through Deep Tech
Data Collective Tops Up Previously Closed Fifth and Sixth Funds for a New Total of $387 Million
Big Data Strikes Back: The Rise of Image, Sensor, and Genome Data Powering Deep Vertical Startups
In The Media
Atomwise Raises $123m Series B For Breakthrough Drug Discovery Platform
Atomwise Announces Three More Drug Discovery Partnerships – Driving $6b total value contracts in last 9 months
Newsweek talks to Atomwise CEO Abraham Heifets About His Moonshot – Using AI to Discover Better & Safer Drugs for Cancer Patients
AI-driven drug discovery startup Atomwise raises $45M series A
Explore Companies
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules